These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2201503)

  • 1. Immunosuppression in IDDM. Rationale, risks, benefits, and strategies.
    Mahon JL; Dupré J; Stiller CR; Donner AP
    Diabetes Care; 1990 Jul; 13(7):806-8. PubMed ID: 2201503
    [No Abstract]   [Full Text] [Related]  

  • 2. Insulin-dependent diabetes: strategy for immune intervention.
    Debray-Sachs M; Feutren G; Boitard C; Assan R; Bach JF
    Exp Clin Endocrinol; 1987 Aug; 89(3):297-300. PubMed ID: 3666048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporin therapy for prevention and cure of IDDM. Epidemiological perspective of benefits and risks.
    Lipton R; LaPorte RE; Becker DJ; Dorman JS; Orchard TJ; Atchison J; Drash AL
    Diabetes Care; 1990 Jul; 13(7):776-84. PubMed ID: 2201500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of immunosuppression with cyclosporine in insulin-dependent diabetes mellitus of recent onset: the Canadian open study at 44 months.
    Dupré J; Stiller CR; Gent M; Donner A; von Graffenreid B; Murphy G; Heinrichs D; Jenner MR; Keown PA; Laupacis A
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):184-92. PubMed ID: 3289204
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclosporin for diabetes?
    Lancet; 1986 Jul; 2(8499):140. PubMed ID: 2873403
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunosuppression in the treatment of insulin-dependent (type 1) diabetes.
    Rubenstein AH; Pyke D
    Lancet; 1987 Feb; 1(8530):436-7. PubMed ID: 2880226
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunosuppression for insulin-dependent diabetes.
    Herold KC; Rubenstein AH
    N Engl J Med; 1988 Mar; 318(11):701-3. PubMed ID: 3344022
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of immunosuppression with cyclosporine on beta cell function and clinical remission in very early overt type I diabetes.
    Dupre J; Stiller CR
    Adv Exp Med Biol; 1988; 246():347-55. PubMed ID: 3074665
    [No Abstract]   [Full Text] [Related]  

  • 9. Cyclosporin A in treatment of new-onset type I diabetes mellitus.
    O'Brien D; Butler N; Chase HP; Hammon R; Hayward A; Klingensmith G; Pontesilli O
    Diabetes Care; 1988 Mar; 11(3):297. PubMed ID: 3046855
    [No Abstract]   [Full Text] [Related]  

  • 10. [Sandoz-INSERM randomized trial of cyclosporine in type I insulin-dependent diabetes].
    Feutren G; Bach JF
    Diabete Metab; 1985 Jun; 11(3):191-3. PubMed ID: 3896887
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclosporine, combination immunosuppression, and posttransplant diabetes mellitus.
    Boudreaux JP; McHugh L; Canafax DM; Asher N; Sutherland DE; Payne W; Simmons RL; Najarian JS; Fryd DS
    Transplant Proc; 1987 Feb; 19(1 Pt 2):1811-3. PubMed ID: 3079040
    [No Abstract]   [Full Text] [Related]  

  • 12. [Immunosuppression in juvenile diabetes mellitus? Critical viewpoint on the treatment with cyclosporin A with consideration of the differential etiology].
    Teuber J; Usadel KH
    Fortschr Med; 1985 Jul; 103(27-28):707-13. PubMed ID: 4029865
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclosporine trials in diabetes: updated results of the French experience.
    Assan R; Feutren G; Sirmai J
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):178-83. PubMed ID: 3289203
    [No Abstract]   [Full Text] [Related]  

  • 14. [Immunosuppressive therapy in type 1 diabetes: update].
    Pozzilli P
    Recenti Prog Med; 1987 Nov; 78(11):514-6. PubMed ID: 3324237
    [No Abstract]   [Full Text] [Related]  

  • 15. [Immunotherapeutic management of juvenile diabetes mellitus].
    Moncada E
    Rev Esp Fisiol; 1989; 45 Suppl():301-8. PubMed ID: 2701766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Induction of remissions of insulin-dependent diabetes by cyclosporin].
    Feutren G; Papoz L; Assan R; Vialettes B; Pehuet M; Vexiau P; Durostu H; Rodier M; Sirmai J; Lallemand A
    C R Acad Sci III; 1986; 303(8):295-7. PubMed ID: 3094846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive therapy in newly diagnosed diabetic children (comparison between two different strategies).
    Pocecco M; Marinoni S; Tonini G; Tedesco F
    J Endocrinol Invest; 1989; 12(8 Suppl 3):143-4. PubMed ID: 2809092
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of low-dose cyclosporine prophylaxis in nonobese diabetic mice.
    Formby B; Miller N; Garret R; Peterson CM
    J Pharmacol Exp Ther; 1987 Jun; 241(3):1106-11. PubMed ID: 3298620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of predictive value of islet cell antibodies, insulin antibodies, and HLA-DR phenotype for remission in cyclosporin-treated IDDM patients. The Canadian-European Randomized Control Trial Group.
    Mandrup-Poulsen T; Mølvig J; Andersen HU; Helqvist S; Spinas GA; Munck M
    Diabetes; 1990 Feb; 39(2):204-10. PubMed ID: 2227128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials of cyclosporin in IDDM.
    Dupré J; Stiller CR; Gent M; Donner A; von Graffenried B; Heinrichs D; Jenner M; Keown P; Mahon J; Martell R
    Diabetes Care; 1988; 11 Suppl 1():37-44. PubMed ID: 3069390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.